



## Absorica® (isotretinoin) – First-time generic

- On April 30, 2021, [Teva launched](#) an [AB-rated](#) generic version of Sun's [Absorica \(isotretinoin\)](#) capsules.
  - [Upsher-Smith](#) received FDA approval of an AB-rated generic version of Absorica on April 12, 2021; launch plans are pending.
- Absorica is approved for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater.
- Isotretinoin is also available as branded capsules (Absorica LD), generic [capsules](#), and branded generic capsules ([Amnesteem](#)®, [Claravis](#)®, [Myorisan](#)®, and [Zentane](#)®).
  - All products carry similar indications to Absorica.
- Absorica carries a boxed warning for embryo-fetal toxicity – contraindicated in pregnancy.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.